FIGURE 1.

Effects of combined administration of RvE1 and LXA4 on pro‐inflammatory factor expression. (A) Expression of RelA mRNA in LPS‐induced DPFs after treatment with four representative specialized pro‐resolving mediators. (B) Expression of RelA mRNA in LPS‐induced DPFs after treatment with RvE1 or LXA4 alone, and a combination of RvE1 and LXA4. (C) NLRP3, (D) caspase‐1, (E) IL‐1β and (F) IL‐18 mRNA levels on LPS‐induced DPFs detected by qPCR and (G) their protein levels tested by western blotting (normalized to that of β‐tubulin). (H) IL‐1β and (I) IL‐18 protein levels from cultural supernatant detected by ELISA. Other NF‐κB‐dependent expression of genes (J) IL‐6, (K) TNF‐α, (L) CCL2 and (M) CCL7 detected by qPCR. (*p < 0.05 and **p < 0.01). DPFs, dental pulp fibroblasts; ELISA, enzyme‐linked immunosorbent assay; LPS, lipopolysaccharide; LXA4, lipoxin A4; NF‐κB, nuclear factor kappa B; qPCR, quantitative polymerase chain reaction; RvE1, resolvin E1